B of A Securities Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $314
Portfolio Pulse from Benzinga Newsdesk
B of A Securities has maintained a Buy rating on Alnylam Pharmaceuticals and raised its price target from $307 to $314.
October 14, 2024 | 5:50 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
B of A Securities has reaffirmed its Buy rating on Alnylam Pharmaceuticals and increased the price target from $307 to $314, indicating confidence in the company's future performance.
The increase in price target from $307 to $314 by B of A Securities suggests a positive outlook on Alnylam Pharmaceuticals' future performance. This is likely to boost investor confidence and potentially lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100